Le Lézard
Classified in: Health
Subject: AWD

Prescryptive Is Named a Premier Partner by ConsenSys for Blockchain in Healthcare


REDMOND, Wash., Jan. 25, 2022 /PRNewswire/ -- Prescryptive Health, a healthcare technology company empowering consumers, today announced that blockchain leader ConsenSys has named the company a premier partner for its expertise in the Quorum Blockchain Service (QBS). QBS is a permissioned blockchain based on Ethereum that gives enterprises the ability to grow and operate blockchain networks at scale. With blockchain, Prescryptive can place consumers at the center of their healthcare experience by enabling transparency and control of health plan data, prescription drug pricing and affordability options, better interactions with prescribers and pharmacists, and the ability to "own" their electronic prescriptions for the first time.

Prescryptive's use of QBS allows it to meet the needs of its fast-growing network of consumers, pharmacists, employers, and pharma partners. Blockchain helps to alleviate healthcare industry burdens around data, audit/reconciliation, and transparency while lowering costs and improving security. Today, Prescryptive's health intelligence platform connects hundreds of thousands of patients on its network of over 60,000 pharmacies nationwide via the platform's consumer mobile app, MyRx.io.  

"Prescryptive was an early adopter of blockchain, showing an understanding of how the technology will transform the digital health landscape," said Marc Mercuri, SVP, Developers at ConsenSys. "The company brought the same level of expertise in how it approached and implemented QBS, which will power the next generation of blockchain networks. We are excited by our work with Prescryptive and by the advantages they will bring to the digital healthcare marketplace." 

"Our goal in 2017 when we began building a new health intelligence platform on blockchain was to empower consumers with modern digital healthcare experiences," said Tony Little, Vice President of Product at Prescryptive. "Our work with ConsenSys has set the stage for the next evolution of services and capabilities utilizing Web3 innovations, driving tremendous levels of data transparency and financial savings across the industry."

About Prescryptive Healthcare
Prescryptive Health is a healthcare technology company delivering solutions that empower consumers. Prescryptive's secure, mobile-first products connect consumers, pharmacists, and employers, ultimately providing people with the information they need to make informed decisions and take control of their health. To learn more about Prescryptive Health, visit www.prescryptive.com.

About ConsenSys

ConsenSys is the leading Ethereum software company. We enable developers, enterprises, and people worldwide to build next-generation applications, launch modern financial infrastructure, and access the decentralized web. Our product suite, composed of Infura, Quorum, Codefi, MetaMask, Truffle, Diligence and our NFT platform, serves millions of users, supports billions of blockchain-based queries for our clients, and has handled billions of dollars in digital assets. Ethereum is the largest programmable blockchain in the world, leading in business adoption, developer community, and DeFi activity.  On this trusted, open source foundation, we are building the digital economy of tomorrow. To explore our products and solutions, visit http://consensys.net/.

SOURCE Prescryptive Health


These press releases may also interest you

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...



News published on and distributed by: